The Clinical Liver Safety Assessment Best Practices Workshop: Rationale, Goals, Accomplishments and the Future

Avoiding idiosyncratic DILI: Two is better than one

(2013) Neil Kaplowitz   HEPATOLOGY

Adverse Event Reporting in Cancer Clinical Trial Publications

(2013) Shanthi Sivendran et al.   JOURNAL OF CLINICAL ONCOLOGY

REMOVED: An Overview of Emerging Therapies for the Treatment of Chronic Hepatitis C

(2013) Jawad A. Ilyas et al.   MEDICAL CLINICS OF NORTH AMERICA

Preparing for Responsible Sharing of Clinical Trial Data

(2013) Michelle M. Mello et al.   NEW ENGLAND JOURNAL OF MEDICINE

What Does the Food and Drug Administration Safety and Innovation Act Mean For You?

(2013) Gary D. Novack   Ocular Surface

Alanine Aminotransferase: A Clinical and Regulatory Tool for Detecting Liver Injury–Past, Present, and Future

(2012) J R Senior   CLINICAL PHARMACOLOGY & THERAPEUTICS

Is poor research the cause of the declining productivity of the pharmaceutical industry? An industry in need of a paradigm shift

(2012) Frank Sams-Dodd   DRUG DISCOVERY TODAY

Humanized mice: Current states and perspectives

(2012) Sylvie Garcia et al.   IMMUNOLOGY LETTERS

Drug Safety Sciences and the Bottleneck in Drug Development

(2011) P B Watkins   CLINICAL PHARMACOLOGY & THERAPEUTICS

Evaluation of Drug-Induced Serious Hepatotoxicity (eDISH)

(2011) Paul B. Watkins et al.   DRUG SAFETY

HLA-DQA1*02:01 Is a Major Risk Factor for Lapatinib-Induced Hepatotoxicity in Women With Advanced Breast Cancer

(2011) Colin F. Spraggs et al.   JOURNAL OF CLINICAL ONCOLOGY

A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury

(2010) Jonathan B Singer et al.   NATURE GENETICS

Monitoring for Hepatotoxicity: What Is the Predictive Value of Liver “Function” Tests?

(2009) JR Senior   CLINICAL PHARMACOLOGY & THERAPEUTICS

The future of drug safety testing: expanding the view and narrowing the focus

(2009) James L. Stevens et al.   DRUG DISCOVERY TODAY